The shares of Great Basin Scientific Inc (NASDAQ:GBSN) are trading 14.81% higher from their closing price yesterday as the company announced the commercial launch of its Group B Strep Test. The molecular diagnostic testing company has reported an excellent response from the market and this is the second successful test launch from the company after its clostridium difficile (C. diff) test. The Group B Streptococcus (GBS) test received approval from the U.S. Food and Drug Administration in April and it will be available for use in U.S. hospitals and laboratories after the launch.
Vista Labs is among one of the earliest adopters of the GBS test and the stand-alone reference lab said, “The ease of use with no prep steps to run this assay—compared to our prior non-molecular method—provided a huge incentive for us to adopt this test.” While discussing the response from the market, the Chief Executive Officer and co-founder of Great Basin Scientific Inc (NASDAQ:GBSN), Ryan Ashton, said, “Initial response to our GBS test has exceeded our expectations. We believe this speaks to an unmet need in the market that Great Basin addresses by delivering simplified workflow, at appropriate cost, and the sensitivity, specificity and speed of molecular testing that our lab customers demand…”
Earlier in June, the National Institutes of Health (NIH) gave a $5 million grant to Great Basin Scientific Inc (NASDAQ:GBSN) and Brigham Young University for the purposes of developing a test to detect bacteria responsible for carbapenem-resistant Enterobacteriaceae (CRE). The grant is a part of President Obama’s National Action Plan for Combating Antibiotic-Resistant Bacteria mission and it will help the company in developing a diagnostic test that could detect the bacteria within an hour. Under the terms of the grant, the test is being developed to detect the presence of bacteria in a whole blood specimen within an hour of initialization. Robert Jenison, Chief Technology Officer and VP of Research and Development, said, “By avoiding time-consuming sample purification and multiplex limitations of traditional polymerase chain reaction (PCR) tests, we are working towards offering better clinical outcomes for those infected with CRE and other deadly superbugs – especially critical given the rising incidence of CRE outbreaks like those we saw recently in California.”
Great Basin Scientific Inc (NASDAQ:GBSN) has had a spectacular run in 2015, with shares growing by 33.52% year-to-date. Unfortunately for hedge funds, they have had little part of it, as only Ken Griffin’s Citadel Investment had a stake in the company of the funds we track, and a miniscule one at that, of just under 12,000 shares valued at $47,000; literally a drop in the ocean of the fund’s greater than $104 billion public equity portfolio. As for the insider activity at the company, insiders at Great Basin Scientific have not made any transactions in the past six months.
Why are we interested in the 13F filings of a select group of hedge funds? We use these filings to determine the top 15 small-cap stocks held by these elite funds based on 16 years of research that showed their top small-cap picks are much more profitable than both their large-cap stocks and the broader market as a whole. These small-cap stocks beat the S&P 500 Total Return Index by an average of nearly one percentage point per month in our backtests, which were conducted over the period of 1999 to 2012. Moreover, since the beginning of forward testing from August 2012, the strategy worked just as our research predicted, outperforming the market every year and returning 135% over the last 32 months, which is more than 80 percentage points higher than the returns of the S&P 500 ETF (SPY) (see more details).
In case of companies associated with the healthcare industry, a single drug approval and diagnostic method could help them gain necessary momentum. In light of the recent commercial launch of Great Basin Scientific Inc (NASDAQ:GBSN)’s GBS test, we recommend a buy for the shares of the company.
Disclosure: None